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Aims Reducing maternal mortality is a World Health Organization (WHO) global health goal. Although maternal deaths
due to haemorrhage and infection are declining, those related to heart disease are increasing and are now the
most important cause in western countries. The aim is to define contemporary diagnosis-specific outcomes in
pregnant women with heart disease.
...................................................................................................................................................................................................
Methods
and results
From 2007 to 2018, pregnant women with heart disease were prospectively enrolled in the Registry Of Pregnancy
And Cardiac disease (ROPAC). Primary outcome was maternal mortality or heart failure, secondary outcomes
were other cardiac, obstetric, and foetal complications. We enrolled 5739 pregnancies; the mean age was 29.5.
Prevalent diagnoses were congenital (57%) and valvular heart disease (29%). Mortality (overall 0.6%) was highest in
the pulmonary arterial hypertension (PAH) group (9%). Heart failure occurred in 11%, arrhythmias in 2%. Delivery
was by Caesarean section in 44%. Obstetric and foetal complications occurred in 17% and 21%, respectively. The
number of high-risk pregnancies (mWHO Class IV) increased from 0.7% in 2007–2010 to 10.9% in 2015–2018.
Determinants for maternal complications were pre-pregnancy heart failure or New York Heart Association >II,
systemic ejection fraction <40%, mWHO Class 4, and anticoagulants use. After an increase from 2007 to 2009,
complication rates fell from 13.2% in 2010 to 9.3% in 2017.
...................................................................................................................................................................................................
Conclusion Rates of maternal mortality or heart failure were high in women with heart disease. However, from 2010, these rates
declined despite the inclusion of more high-risk pregnancies. Highest complication rates occurred in women with PAH.
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Introduction
Maternal heart disease complicates between 1% and 4% of pregnan-
cies, and accounts for up to 15% of maternal deaths.1,2 According to
the most recent statistics from the World Health Organization
(WHO), maternal mortality in developed economies is around 12
per 100 000 live births (0.012%) and 239 per 100 000 live births
(0.2%) in emerging economies, with large disparities both between
and within countries.3 While leading causes such as haemorrhage and
infection are declining, mortality due to maternal heart disease is
increasing2,4,5 and in developed countries, heart disease is now the
leading cause. The burden of maternal heart disease is expected to in-
crease due to improved survival of women with congenital heart dis-
ease (CONHD) and the trend to delay motherhood, with the
associated rise in comorbidities such as metabolic syndrome. Thus,
heart disease may become an even greater contributor to maternal
deaths worldwide.2
Research is difficult to perform in the field of heart disease and
pregnancy and observational studies such as CARPREG and
ZAHARA have been the primary source of evidence.6–9 Large pro-
spective registries were needed to improve the quality and level of
knowledge relating to this growing population. Therefore, in 2007,
the EURObservational Research Programme (EORP) of the European
Society of Cardiology (ESC) established the Registry Of Pregnancy
And Cardiac disease (ROPAC). This important data source assembles
granular clinical data on large numbers of pregnant patients with heart
disease from real-life daily practice, informing our understanding of the
outcomes in this population with the ultimate goal of improving patient
outcomes. An interim analysis of the first 1321 patients was reported
in 201310 and an overview of the full registry is presented here.
The aims of the current study are to provide contemporary infor-
mation on the impact of a wide range of cardiovascular diseases on
maternal and foetal mortality and morbidity and identify key areas
where current management can be improved.
Methods
Study design
The Registry Of Pregnancy And Cardiac disease (ROPAC) is an inter-
national, prospective, observational registry of pregnant women with
CONHD, valvular heart disease (VHD), cardiomyopathy (CMP), or is-
chaemic heart disease (IHD). Pregnancies were included prospectively
from January 2007 until January 2018. From 2013, patients with pulmon-
ary arterial hypertension (PAH) or aorta pathology (AOP) were also
enrolled. An interim analysis of the first 1321 pregnancies (PREG1) was
published in 2013. Comparisons were made between the PREG1 and the
data collected from 2011 onwards (PREG2). We included data from all
pregnancies up to 1 week post-partum. Women with a primary diagnosis
of PAH or AOP were excluded from the analysis of trends over time be-
cause they have not been enrolled in ROPAC from the start of the
registry.
Data, definitions, study endpoints, and
statistical analysis
The study protocol, methods, and the outcomes of the first 1321 preg-
nancies included were published in 2013.10 The primary endpoint was
maternal mortality and/or heart failure. Information on data, definitions,
endpoints, and statistical methods can be found in the Supplementary ma-
terial online, Appendix.
Results
A total of 5739 pregnancies were recruited from 138 centres in 53
countries. The list of participating centres is given in the
Supplementary material online, Appendix. Sixty percent of women
were from developed countries. The mean maternal age was
29.5 years, and 45% were nulliparous. There were 96 twin pregnan-
cies (1.7%). The baseline characteristics for PREG1, PREG2, and the
total cohort are presented in Table 1. Details of diagnosis are shown
in Supplementary material online, Figure S1. There were missing data
in 1.7% of baseline variables.
Table 2 summarizes the cardiovascular, obstetric, and foetal out-
comes, for PREG1, PREG2, and the total cohort. In Supplementary
material online, Tables S1–S3, the baseline characteristics and out-
comes are summarized per diagnostic group and divided in emerging
and developed countries and in Supplementary material online, Table
S4, the differences in characteristics and outcome are compared be-
tween women who have undergone pre-conceptional counselling
and those who have not.
The PREG1 and the PREG2 cohorts differed significantly with re-
spect to the percentage nulliparous women (49.2% vs. 43.5%,
P< 0.001), women from emerging countries (21.3% vs. 45.3%,
P< 0.001), women with a diagnosis of CONHD (62.0% vs. 56.0%,
P< 0.001), prior interventions (61.3% vs. 53.2%, P< 0.001), and pre-
pregnancy cardiac medication use (20.4% vs. 40.8%, P< 0.001). Also,
the distribution of women in the different mWHO classes differed
significantly, the most remarkable difference being the percentage of
women in mWHO IV.
Maternal cardiovascular outcome and
clinical determinants of study endpoint
Maternal mortality and/or heart failure occurred in 629 pregnancies
(11%), with maternal death in 34 women (0.6%). In four cases, the
cause of death was unknown and five patients died from non-cardiac
causes, four of these being septic shock. Refractory heart failure was
the cause of death in 15 patients, five of which were related to severe
PAH. Four patients died from complications of mechanical valve
thrombosis, two from endocarditis, two patients from primary car-
diac arrest with ventricular fibrillation, and two other patients from
haemodynamic complications following abortion and pulmonary em-
bolism, respectively.
2 J. Roos-Hesselink et al.
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.Heart failure complicated 611 pregnancies (11%), of which 44
(7%) occurred solely postpartum. In women with a mechanical valve,
22 (7%) pregnancies were complicated by valve thrombosis, which
was lethal in four (18%). Of the six women with known valvular re-
placement surgery none died, while of the two women with known
thrombolytic therapy one died due to intracerebral haemorrhage.
Supplementary material online, Table S5 shows the women with valve
thrombosis and their outcome. In the AOP group, aortic dissection
occurred in four (1.8%), at a mean of 34 weeks gestation. In Figure 1,
the occurrence of cardiovascular events is summarized for the differ-
ent diagnosis groups and in Supplementary material online, Figure S2,
it is subdivided for the additional sub-groups. Within PREG1 were
significantly less thrombotic events compared with PREG2 (0.5% vs.
1.8%, P= 0.006).
In Figure 2, the results from the regression analyses are shown for
the primary outcome for the total cohort. Pre-pregnancy New York
Heart Association (NYHA) >II, systemic ventricular ejection fraction
(EF) of <40%, signs of heart failure, mWHO IV, and anticoagulation use
were independent predictors of the occurrence of death/heart failure.
Study endpoints over time
The incidence of death/heart failure changed over time (Figure 3).
Assuming a linear trend since 2007, the annual incidence decreased
by 0.8%/year (P< 0.001). However, our data suggest that there was
an early increase until 2010, with a subsequent annual decrease of
1.3%/year (P< 0.001) thereafter. Noteworthy, this decline was
reached, while the percentage of mWHO IV patients increased from
around 1% in the first years up to 10% in the last years
(Supplementary material online, Figure S3). Time trends were similar
in the three main diagnostic groups, but most pronounced in CMP.
Supplementary material online, Figure S5 shows trend analyses for
emerging and developed countries.
Obstetric and foetal outcome
A total of 992 pregnancies (17%) were complicated by obstetric
events during pregnancy. Emergency caesarean section was per-
formed in 537 pregnancies (9%), 84 (16%) were for cardiac reasons.
Preeclampsia occurred in 3% and was seen more commonly in
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of PREG1 and PREG2 cohorts and the total cohort
Total cohort
(n5 5739)
PREG1 cohort
(n5 1321)
PREG2 cohort
(n54418)
P-value
Demographics
Age, mean (SD) 29.5 (5.6) 29.2 (5.7) 29.6 (5.6) 0.01
Nulliparity 2573 (44.8%) 652 (49.2%) 1921 (43.5%) <0.001
Emerging country 2281 (39.7%) 282 (21.3%) 1999 (45.3%) <0.001
Diagnosis
Congenital heart disease 3295 (57.4%) 822 (62.0%) 2473 (56.0%) <0.001
Valvular heart disease 1648 (28.7%) 341 (25.7%) 1307 (29.6%) 0.01
Cardiomyopathy 438 (7.6%) 91 (6.9%) 347 (7.9%) 0.23
Pregnancy-induced during current pregnancy 23 (5.3%)a 0 (0%) 23 (6.6%) <0.001
Ischaemic heart disease 95 (1.6%) 26 (2.0%) 69 (1.6%) 0.32
Pre-pregnancy clinical characteristics
Current smoking 228 (4%) 45 (3.3%) 183 (4.1%) 0.34
Hypertension 380 (7%) 88 (6.7%) 292 (6.6%) 0.89
History of diabetes mellitus 90 (2%) 21 (1.6%) 69 (1.6%) 1
History of atrial fibrillation 106 (2%) 24 (1.8%) 82 (1.9%) 0.91
Signs of heart failure 596 (11%) 136 (10.3%) 460 (10.4%) 0.88
Prior intervention 3160 (55%) 812 (61.3%) 2348 (53.2%) 0.08
NYHA class 0.35
I 4207 (73.3%) 937 (70.7%) 3270 (74.1%)
II 1191 (20.8%) 323 (24.5%) 868 (19.7%)
III 176 (3.1%) 40 (3.0%) 136 (3.1%)
IV 28 (0.5%) 4 (0.3%) 24 (0.5%)
Cardiac medication 2069 (36.1%) 270 (20.4%) 1799 (40.8%) <0.001
mWHO class 0.05
I 1185 (20.6%) 284 (21.4%) 901 (20.4%)
II 828 (14.4%) 226 (17.1%) 602 (13.6%)
II–III 2698 (47.0%) 720 (54.3%) 1978 (44.8%)
III 593 (10.3%) 88 (6.6%) 505 (11.4%)
IV 407 (7.1%) 7 (0.5%) 400 (9.1%)
P-values were calculated between the PREG1 and PREG2 cohorts (independent samples t-test and v2 tests where appropriate).
aPercentage of cardiomyopathies.
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patients with CMP and PAH (7% and 11%, respectively). In women
with peripartum CMP during current pregnancy (n= 23), six contem-
poraneously suffered from preeclampsia (26.1%).
In 1186 pregnancies (21%), one or more foetal complications
occurred. In particular prematurity was prevalent (16%). These rates
were highest in patients with CMP (26%), PAH (49%), and AOP
(21%). In Supplementary material online, Figure S6, the occurrence of
obstetric and foetal events is summarized per diagnostic group.
Cardiovascular, and all obstetric and foetal outcomes varied
according to mWHO categories (Supplementary material online,
Figure S3).
Discussion
ROPAC is a prospective registry containing 5739 pregnancies in
women with structural and IHD, PAH, and AOP. This is by far the
largest registry of its kind ever undertaken. The overall maternal mor-
tality rate in our study was 0.6%, which is much higher than that
observed in the normal pregnant population.11 The most important
complication found in our registry is heart failure, which complicated
11% of pregnancies, of which 7% occurred for the first time in the
first week postpartum. These results highlight that intensive manage-
ment and monitoring of women at risk of heart failure is essential
throughout pregnancy and also after delivery.
....................................................................................................................................................................................................................
Table 2 Outcomes of PREG1 and PREG2 cohorts and the total cohort
Total cohort
(n55739)
95% CI PREG1 cohort
(n5 1321)
95% CI PREG2 cohort
(n5 4418)
95% CI P-value
Cardiovascular outcome
Maternal mortality and/or heart failure 629 (11.0%) 10.2–11.8% 161 (12.2%) 10.5–14.1% 468 (10.6%) 9.7–11.5% 0.11
Maternal mortality 34 (0.6 %) 0.4–0.8% 9 (0.7%) 0.4–0.13% 25 (0.6%) 0.4–0.8% 0.63
Heart failure event 611 (10.6%) 9.9–11.5% 153 (11.5%) 10.0–13.4% 458 (10.3%) 9.5–11.3% 0.29
Supraventricular arrhythmia 95 (1.7%) 1.4–2.0% 11 (0.9%) 0.5–0.15% 84 (1.9%) 1.5–2.3% 0.06
Ventricular arrhythmia 90 (1.6%) 1.3–1.9% 27 (2.0%) 1.4–3.0% 63 (1.4%) 1.1–1.8% 0.30
Thrombotic event 87 (1.5%) 1.2–1.9% 6 (0.5%) 0.2–1.0% 81 (1.8%) 1.5–2.3% 0.006
Aortic dissection 5 (0.1%) 0.0–0.2% 0 (0%) 0.0–0.3% 5 (0.1%) 0.0–0.3% 0.22
Obstetric outcome
Pregnancy-induced hypertension 150 (2.6%) 2.2–3.1% 25 (2.4%) 1.3–2.8% 125 (2.8%) 2.4–3.4% 0.57
(Pre-)eclampsia 159 (2.8%) 2.4–3.2% 44 (3.3%) 2.5–4.4% 115 (2.6%) 2.2–3.1% 0.35
Post-partum haemorrhage 170 (3.0%) 2.6–3.4% 38 (2.9%) 2.1–3.9% 132 (3.0%) 2.5–3.5% 0.89
Caesarean section 2681 (46.7%) 45.4–48.0% 538 (40.6%) 38.1–43.3% 2143 (48.6%) 47.0–50.0% <0.001
Emergency caesarean section 766 (13.3%) 12.5–14.3% 204 (15.4%) 13.6–17.5% 562 (12.7%) 11.8–13.7% 0.01
Foetal outcome
Foetal mortality 72 (1.3%) 1.0–1.6% 20 (1.5%) 1.0–2.3% 52 (1.2%) 0.9–1.5% 0.56
Neonatal mortality 33 (0.6%) 0.4–0.8% 8 (0.6%) 0.3–1.2% 25 (0.6%) 0.4–0.8% 0.88
Premature birth 905 (15.8%) 14.8–16.7% 200 (15.1%) 13.3–17.2% 705 (16.0%) 14.9–17.1% 0.58
Low apgar scores 397 (6.9%) 6.3–7.6% 95 (7.2%) 5.9–8.7% 282 (6.4%) 5.7–7.1% 0.48
IUGR 254 (4.4%) 3.9–5.0% 70 (5.3%) 4.2–6.6% 184 (4.2%) 3.6–4.8% 0.25
Low birth weight 673 (11.7%) 10.9–12.6% 12 (0.9%) 0.5–1.6% 661 (15.0%) 13.9–16.0% <0.001
P-values were calculated between the PREG1 and PREG2 cohort (v2 tests). All events were monitored between enrolment date (start of pregnancy or first trimester) and
1 week after delivery.
Figure 1 The occurrence of maternal cardiovascular events for
the different diagnosis groups. AOP, aortic pathology; CMP, cardio-
myopathy; CONHD, congenital heart disease; IHD, ischemic heart
disease; PAH, pulmonary arterial hypertension; VHD, valvular heart
disease.
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One of the WHO Millennium Development Goals was to reduce
maternal deaths by 75% between 1990 and 2015; this was partially
successful, as the rate fell by 44%.3 The new Sustainable
Development Goals have targeted a reduction in worldwide mater-
nal mortality to <70 deaths per 100 000 live births by 2030.3 To
achieve this target, the rate of decline in maternal mortality will have
to increase to 7.5% per year. This is unlikely to be achieved unless the
increasing contribution to mortality made by heart disease is
reversed. Data from ROPAC can help by determining which patients
are at high risk and identifying areas in which the greatest improve-
ments can be achieved.
Diagnostic groups: low-risk and high-risk
patients
The highest mortality/heart failure rates were found in women with
PAH, CMP, and VHD as also described by previous series.12–20 The
trends over time showed that especially in VHD and CMP there was
a decrease in maternal mortality or heart failure, while in CONHD
Figure 2 Univariable and multivariable logistic regression analysis for the primary endpoint or heart failure. All variables used in this regression
were pre-pregnancy characteristics.
Figure 3 The trends over time in death or heart failure, for the overall cohort and for the three largest diagnosis groups. The number of total
included pregnancies and the percentage inclusion of mWHO class IV in the corresponding year are shown below the figures, in total as well as for
the diagnosis groups. The data points represent the number of death and/or heart failure per year. Time trends were analysed by linear mixed effect
models with the logit link function (see Methods section). The model that we fitted for the overall cohort was as follows: logit (endpoint) = -2.447þ
0.524  s – 0.130  t2 þ 0.008  t3, with t = time since 1 January 2007. The significance of the respective regression coefficients was as follows:
<0.001, 0.003, 0.002, 0.002. , Cardiomyopathy; , Valvular heart disease; , Overall cohort; , Congenital heart disease.
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..the rate was and remained low. Our study emphasizes that patients
with PAH are still, despite advances in management, a high-risk group
and that they should be advised against pregnancy.
The mortality rate for the CMP group was 1.1% and heart failure
occurred in 28%. Current guidelines advise against pregnancy if the
systemic ventricular EF is <30%.12 Our data suggest that all patients
with dilated CMP, even with relatively preserved EF, are high risk and
should be counselled accordingly.21–23
Patients with CONHD constitute the largest subgroup within this
registry and have a relatively favourable pregnancy outcome,10 with a
mortality rate of 0.2%. However, due to the heterogeneous nature of
this group, the type and complexity of CONHD need to be taken
into account. Indeed, the heart failure rate in the patients with com-
plex CONHD was 13%, while it was 5% and 6% for the simple and
moderate defects, respectively. The vast majority of patients had
their condition diagnosed and treated at a young age, allowing ample
opportunity for pre-pregnancy counselling and optimization prior to
pregnancy, perhaps accounting for the relatively good outcomes.
In the AOP group, the rate of dissection was 1.8% and we found a
strikingly high rate of delivery by caesarean section (52%). There are
limited data on the effect of labour and active pushing on the risk of
aortic dissection, and current guidelines are solely based on expert
opinion.24–26 Many physicians feel safe when using caesarean section,
however, using epidural anaesthesia with the avoidance of pushing
might be as good or even better for mother and baby,27 but more re-
search is clearly required to investigate the optimal mode and timing
of delivery in these women. A dedicated ROPAC registry for patients
with AOP just started within the EORP, to further analyse the risks
and outcomes during pregnancy.
A large proportion of patients with VHD had rheumatic heart dis-
ease (56%). These women show a tendency to present late in preg-
nancy, meaning that those caring for them often only become aware
of the condition when complications arise.28 This may explain the
high rates of maternal mortality (1%) and heart failure (17%) in this
group. Especially severe mitral stenosis is associated with high compli-
cation rates.28 Seven percent of patients with a mechanical valve suf-
fered from valve thrombosis, of which 18% died. There is still no
consensus with respect to the best anticoagulation strategy,29–32 an-
other area where research is urgently required. Women with a
mechanical prosthesis are currently classified as mWHO III.
However, given the high rates of severe and potentially lethal compli-
cations and miscarriages, perhaps Class IV is more appropriate and a
particular cautious approach is warranted to counselling these women
and close observation with dedicated supervision is recommended
when pregnancy occurs. In the recently published ESC guidelines on
cardiovascular disease and pregnancy, women with mechanical pros-
theses are now advised to be referred to a tertiary care centre, be-
cause of these high complication rates.1 A dedicated ROPAC registry
for patients with valvular prostheses also started in 2018, to specifically
investigate which anticoagulation regimen is associated with the lowest
risks and to further analyse the outcomes during pregnancy.
The women with IHD were typically older, were more often mul-
tipara and had surprisingly good maternal outcome, with no mortality
and 4% heart failure. Evidence in this field is still very limited and these
patients are often being approached with much caution and preg-
nancy being discouraged. Clearly larger series are required to facili-
tate better counselling.
The results from our study are in line with recommendations from
the 2018 ESC guidelines for the management of cardiovascular dis-
eases during pregnancy.1 Indeed all women with heart disease should
be managed in a hospital. Women in mWHO Class I and II can be
cared for in a local hospital and women in Class II–III in a referral
hospital, while women in Class III and IV should be managed in speci-
alized, tertiary centres by a specialized, multidisciplinary team.
Pre-conceptional counselling is advised for women in all mWHO
classes as it is associated with better outcome.
Take home ﬁgure From 2007 to 2018, pregnant women with heart disease were included in the Registry Of Pregnancy And Cardiac disease
(ROPAC). During that time, the incidence of ‘maternal death or heart failure’ dropped, despite the inclusion of more seriously ill women (mWHO
IV). Especially women with cardiomyopathies or pulmonary arterial hypertension were at risk of ‘maternal death or heart failure’. Pre-pregnancy risk
factors were signs of heart failure prior to pregnancy, NYHA class > II, systemic ventricular ejection fraction of below 40%, mWHO class IV condi-
tions and anticoagulation use.
6 J. Roos-Hesselink et al.
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Clinical determinants of study endpoint
Pre-pregnancy predictors of heart failure and/or mortality were signs
of heart failure or NYHA >II, systemic ventricular EF of <40%,
mWHO IV, and anticoagulants use. This highlights the importance of
pre-conception counselling and optimization of cardiac function be-
fore pregnancy. Some patients can benefit from adjusting or introduc-
ing medication to improve their cardiovascular status before
pregnancy. The use of anticoagulation as a predictor for adverse out-
come is likely to be explained only partly by the effect of the medica-
tion itself. The underlying reason for the medication, such as
mechanical valves, arrhythmias or dilated CMP probably have an
effect.
Study endpoints over time
A remarkable finding was that over the period of the study, an
increasing number of pregnancies in women with mWHO IV disease
were included. This is surprising since conventional advice to women
in this high-risk group is to avoid pregnancy. This is not due to the
later inclusion of patients with PAH and AOP since these groups
were excluded from this analysis. Of course, this increase might be
(partly) explained by selection of patients due to centre and country
inclusion, but clustering within country and site was controlled for.
While recommendations and guidelines are now available and often
discussed with the patients, we cannot prevent women from choos-
ing to become pregnant and we not infrequently encounter high-risk
women who have become pregnant despite our advice. A further ex-
planation of this change in risk profile is that physicians have become
more comfortable with managing women with heart disease, feel bet-
ter capable of dealing with their problems and have therefore modi-
fied their advice. Alternatively, it may simply reflect the existence of
increasing numbers of high-risk patients in the population. Indeed, the
first wave of patients with surgically corrected complex congenital
heart defects such as women with a Fontan circulation are now
reaching adulthood and have the wish to become pregnant. This
increasing number of high-risk pregnancies is a challenge and requires
careful management. Centralization of care for these patients may
optimise outcome. It is also notable, that despite this increase in risk
profile, there was not an increase in mortality with time.
Supplementary material online, Figure S4 shows that there were
around 11% of women in mWHO IV in the years 2015–2017, yet still
the mortality was lower than in the beginning of the study period,
when the proportion mWHO IV was only 1%. In fact, from 2010 to
2011 onwards, the incidence of death or heart failure showed a sig-
nificant decrease. This might indicate greater awareness of the specif-
ic problems and an improvement in the management of pregnant
women with heart disease, which may be related to the publication in
2011 of the first ESC guideline on the management of pregnancy in
women with cardiovascular disease. Although this may be a coinci-
dence, it is possible that the well-publicized availability of this central
resource has led to an increased awareness of the improvement in
management. Of course, the improvement in outcome could also be
associated with political, socioeconomic or access-to-healthcare fac-
tors. Our findings are mirrored by those of the United Kingdom re-
port on maternal mortality which also shows a fall in mortality in
recent years.2 Not surprisingly, we saw the greatest improvement in
outcome in emerging countries, probably because this is where the
mortality was highest and consequently, where the greatest improve-
ment could be achieved.
Limitations
While ROPAC is prospective and the largest registry including all
groups of heart disease, which describes real-life clinical practice, it is
limited by several factors:
• Because we report only mortality up to one week our estimates
are highly likely to have underestimated this component of the pri-
mary endpoint compared with other studies and this should be
considered when making comparison.
• Many pregnant women with heart disease in our cohort were
managed in specialized, tertiary centres with an interest in this
field. The outcomes of other, non-tertiary centres may be different
and caution is required in generalizing our results to the whole
population.
• Although the major advantage of a prospective registry is the way
in which it can document clinical reality, there might still be some
form of selection bias present, as we cannot guarantee (although
it was requested and stressed) that consecutive patients from all
centres were included.
• Some countries and centres have included more patients than
others. Furthermore, the number and constitution of participating
centres varied over time, creating a heterogeneous cohort in
which interpreting results is difficult. However, we adjusted for
this in our analyses.
Conclusions
While pregnancy in women with heart disease in general is associated
with increased risks of maternal mortality (0.6%) and cardiovascular,
obstetric, and foetal complications, many patients tolerate pregnancy
well. Patients with PAH and CMP are at particularly high risk, while
women with simple CONHD have relatively good outcomes.
Pregnancy in women with low-risk conditions should not be discour-
aged, while clear and timely advice not to become pregnant should
be provided to very high-risk women. Pre-pregnancy predictors for
mortality and/or heart failure are NYHA class of >II, mWHO IV, sys-
temic ventricular EF of <40%, signs of heart failure, and the use of
anticoagulants.
Until 2010, maternal mortality and/or heart failure increased.
Thereafter, these rates declined, especially in emerging countries,
despite increasing numbers of high-risk patients. Further studies are
required to assess the optimal management of these patients, with
particular emphasis on cardiac medication use, including anticoagula-
tion regimes and mode of delivery.
Supplementary material
Supplementary material is available at European Heart Journal online.
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